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Summary
Objective: To evaluate antibody persistence one year after three-dose primary vaccination and
booster immune response during the second year of life for a fully liquid diphtheria—tetanus—
acellular pertussis—inactivated poliomyelitis—Haemophilus influenzae type b (DTaP—IPV—
PRPT) vaccine.
Methods: Infants at 18—19months of age were given a booster dose of either DTaP—IPV—PRPT
(group A) or DTaP—IPV plus PRPT at separate injection sites (group B), after primary
vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations
were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent
reports.
Results: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-
PRP antibody titers 0.15 mg/ml. All children had antibody levels believed to protect against
tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one
subject in group A). At least 94% of children still had antibody concentrations 5 ELISA units
(EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin
(PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved
antibody concentrations or titers believed to be protective for PRP (polyribose ribitol
phosphate)(1 mg/ml), diphtheria and tetanus (0.1 IU/ml) and poliovirus types 1, 2, and 3* Corresponding author. Tel.: +33 4 3737 7258
E-mail address: Esteban.Ortiz@sanofipasteur.com (E. Ortiz).
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(8 1/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to
pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from
1.07 to 59.6 mg/ml and from 1.8 to 62.2 mg/ml in groups A and B, respectively. Both vaccine groups
showed low reactogenicity rates.
Conclusions: The fully liquid pentavalent DTaP—IPV—PRPT vaccine is highly immunogenic, with
good antibody persistence for each antigen approximately one year after primary vaccination and
strong booster responses at 18—19 months of age. Because this combined vaccine is fully liquid,
requiring no reconstitution of lyophilized PRPT, the ease of use and proper administration are
improved.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Routine use of pediatric combination vaccines including
acellular pertussis (aP), inactivated poliovirus (IPV) and Hae-
mophilus influenzae type b (Hib) began in Europe and North
America approximately 10 years ago, and has recently
expanded to additional regions. Acellular pertussis vaccines
containing purified Bordetella pertussis antigens were devel-
oped in response to safety concerns relating to whole cell
vaccines. Their efficacy and improved reactogenicity, rela-
tive to whole cell vaccines, has been demonstrated in con-
trolled clinical studies and confirmed in post-market
surveillance of national immunization programs.1,2
One combination, PediacelTM (Sanofi Pasteur), consisting
of five acellular pertussis antigens (aP) plus diphtheria (D)
and tetanus (T) toxoids, inactivated poliovirus types 1, 2, and
3 (IPV), and Haemophilus influenzae type b conjugate vac-
cine (PRPT), has been licensed in the UK and other Eur-
opean countries and several countries in Latin America and
Asia. This combination vaccine protects infants against five
diseases with a series of single injections. A combination
vaccine (PentacelTM, Sanofi Pasteur) containing the same five
acellular pertussis antigens, IPVand a lyophilized formulation
of the same PRPT vaccine has been used universally for the
primary immunization series in Canada since 1998. Nation-
wide surveillance in Canada shows that the incidence of
pertussis in young children has decreased and Hib disease
has remained at very low rates since its introduction, when it
replaced a similar pentavalent whole cell pertussis (DTwP—
IPV//PRPT) combination vaccine.2—6 The DTaP vaccine used
in both the fully liquid combination evaluated here and the
combination containing lyophilized PRPTwas found to have
better reactogenicity and similar immunogenicity when com-
pared to whole-cell pertussis vaccines in controlled clinical
studies, and were at least 85% effective in preventing per-
tussis in large field trials.7—10
In Taiwan a primary vaccination schedule of two, four and
six months and a fourth, booster injection at 18months of age
is followed for these valences. We have recently reported on
the safety and immunogenicity of this DTaP—IPV—PRPT
vaccine for primary vaccination in a group of Taiwanese
infants.11 The response to vaccination was high for all vaccine
antigens. All subjects developed an anti-PRP concentration
of at least 0.15 mg/ml; 97% of subjects given the fully liquid
pentavalent vaccine and 99% given DTaP—IPV and PRPT as
separate injections, developed a concentration of at least
1.0 mg/ml. We report here on the immunogenicity and reac-
togenicity of a booster dose of this vaccine at 18 months of
age compared with the response to the DTaP—IPV and PRPTvaccines given concomitantly at two different sites in the
same infants previously primed with the same vaccine(s).
Materials and methods
Study design
The children included in this open study were healthy, aged
18—19 months, and had earlier been randomized to receive a
three-dose primary series of either DTaP—IPV—PRPT (Pedia-
cel) as a single injection or DTaP—IPV (QuadracelTM) plus
PRPT (ActHibTM) concomitantly at two different injection
sites at two, four and six months of age.11 Infants received a
booster dose of the same vaccine(s) that they had been given
during the primary series. All study subjects had also received
hepatitis B vaccine at 0, one, and six months according to the
Taiwan national schedule, and for which a booster is not
required.
There were two study visits. The booster dose was given at
the first visit after a blood sample was obtained for assess-
ment of antibody persistence. At the second visit, 30—42 days
after the booster, a second blood sample was taken to assess
immune response. This study was conducted in accordance
with the Declaration of Helsinki good clinical practice and
applicable International Conference on Harmonization (ICH)
guidelines. Before enrolment, informed consent was
obtained from the parents or guardians of the children.
The Institutional Review Board of Chang-Gung Memorial
Hospital approved this study.
Children were excluded if they had had any serious
adverse event related to a previous study vaccine dose,
i.e., hypersensitivity, encephalopathy, or hypotonia—hypor-
esponsiveness; fever 40 8C within the 7 days before enrol-
ment; history of seizures or other neurological disorders;
known or suspected immunodeficiency, including human
immunodeficiency virus (HIV) infection; treatment with
immunosuppressive therapies for more than 14 days (exclud-
ing inhaled and topical corticosteroids); or current or
planned receipt of immunoglobulins and/or any blood pro-
ducts. A rectal temperature 38 8C warranted deferral of
enrolment until recovery of the child.
Vaccines
Bothacellular pertussis vaccines contain 20 mgpertussis toxoid
(PT), 20 mg filamentous hemagglutinin (FHA), 5 mg fimbriae 2
and 3 (FIM2+3), 3 mg pertactin (PRN), 15 Lf (limit of floccula-
tion unit) diphtheria toxoid, and 5 Lf tetanus toxoid per 0.5 ml
dose. The IPV in the fully liquid DTaP—IPV—PRPTcombination
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nation is produced in MRC5 human diploid cell culture. Both
poliomyelitis vaccines contain type 1 (Mahoney) 40 D antigen
units, type 2 (MEFI) 8 D antigen units, type 3 (Sankett) 32 D
antigen units. Both combination vaccines also contain 0.33 mg
aluminum phosphate and 0.6% 2-phenoxyethanol per 0.5 ml
dose. The Haemophilus influenzae type b conjugate vaccine
contains 10 mg of purified polyribose ribitol phosphate capsu-
lar polysaccharide (PRP) covalently bound to 20 mg of tetanus
toxoid per 0.5 ml dose. Saline diluent provided in an ampoule
was used to reconstitute the lyophilized PRPTwhen it was
administered concomitantly at a separate injection site. Vac-
cines were administered by intramuscular (IM) injection into
the anterolateral thigh, DTaP—IPV—PRPT and DTaP—IPV in
the left leg, PRPT in the right leg. The study vaccines were
produced and supplied by Sanofi Pasteur, Canada.
Immunogenicity analysis
Antibody assays were performed at Sanofi Pasteur central
laboratories by personnel who were unaware of the subject
study group allocations. Antibodies to PT, FHA, PRN, FIM2+3,
hepatitis B surface antigen (HBsAg) and tetanus antitoxin
were measured by enzyme immunoassay (EIA).12 Diphtheria
antitoxin and anti-polio virus 1, 2, and 3 antibodies were
measured by microneutralization assay in Vero cell culture
and HEp-2 cell culture, respectively.13,14 Anti-PRP antibo-
dies were measured by the Farr radioimmunoassay (RIA)
method and an FDA human reference standard curve.15
Predefined seroprotection (SP) levels were: anti-PRP
0.15 and 1.0 mg/ml; anti-polio 8 (1/dil.); anti-
diphtheria and tetanus 0.01 IU/ml; and anti-HBsAg
10 mIU/ml. Since there are no defined concentrations
for antibodies to pertussis antigens that are known to cor-
relate with protection, vaccine response rates were
assessed as a four-fold increase from pre- to post-booster
concentrations.
Reactogenicity and safety analysis
Members of the study team observed subjects for 30 min-
utes after each injection for any immediate local or sys-
temic reactions. Parents or guardians recorded solicited
local reactions (injection site redness, swelling and pain/
tenderness) or solicited systemic events (fever — rectal
temperature 38 8C, drowsiness, unusual fussiness, unu-
sual crying, loss of appetite, vomiting, and diarrhea) on
diary cards daily for eight days (days 0—7) following each
vaccination. The dates of onset and resolution were
recorded for any unsolicited local or systemic reactions
that occurred within the study period. Temperature was
monitored daily following the eight-day period after vac-
cination if the child remained febrile. Solicited and unso-
licited local and systemic reactions were graded as mild,
moderate or severe. Crying when the limb was moved
indicated severe injection site tenderness. Rectal tem-
perature >40 8C and continuous crying for more than
3 hours were also criteria for severe reactions. Solicited
local and systemic adverse events occurring within the
eight days after vaccination were considered as related
to the administration of the vaccine; events occurring
after eight days were considered as unsolicited.Statistical analysis
The primary study outcomes were seroprotection and vac-
cine response following the booster dose. Seroprotection or
vaccine response rates with 95% confidence intervals (CI)
were calculated for each vaccine antigen before and after
the booster dose in both study groups. Antibody responses to
each vaccine antigen were further described by calculating
their geometric mean titers (GMT), 95% CI and reverse
cumulative distribution curves (RCDC). Concentrations below
the assay level of sensitivity were given a value of one-half of
the assay cut-off for statistical calculations. For evaluation of
reactogenicity, the percentage of subjects with a given
symptom was calculated for each solicited adverse reaction
together with its 95% CI. Statistical comparisons of seropro-
tection or vaccine response rates for each antigen and for the
occurrence of solicited reactions were descriptive, using the
95% CI of the between-group differences.
Results
Subjects
Of the 200 subjects who completed the primary vaccination
series, 174 were enrolled in the booster study; 89 received a
doseof fully liquid combinedDTaP—IPV—PRPTvaccineand85
received separate injections of DTaP—IPV + PRPT. The ages of
the infants in the groups were similar, ranging from 18—22
months. There were more females in the combined vaccine
group (61.8% vs. 47.1%) than in the separate injections group).
Three subjects did not complete the study because of parental
refusal to return to the clinic or to have a home visit.
Immunogenicity
Table 1 summarizes seroprotection and vaccine response
rates for all vaccine antigens one month after completing
the primary vaccination series, at the time of booster admin-
istration, and one month after the booster. The seroprotec-
tion rates at the time of booster administration were high,
and similar between groups for each antigen. One year after
primary vaccination, 93.1% of subjects in the combined
vaccine group and 95.1% in the separate injections group
had anti-PRP antibody concentrations0.15 mg/ml. All study
subjects remained seroprotected against tetanus, and all
against diphtheria except for one child who had received
the fully liquid vaccine. All had anti-poliovirus titers 8 1/
dil. except for type 1 virus in one child who had received
DTaP—IPV + PRPT. When the combination vaccine booster
was given, approximately one year after the three-dose
primary vaccination, the percentage of subjects in the two
study groups who had anti-hepatitis B surface antibody con-
centrations 10 mIU/ml was nearly identical, 97.7% and
97.6%. The anti-HBsAg GMT was 198 mIU/ml in those given
the fully liquid vaccine and 180 mIU/ml in those receiving
DTaP—IPV and PRPT as separate injections.
Post-booster results show that all subjects had anti-PRP
concentrations 1.0 mg/ml, and had antibody concentra-
tions or titers considered to be protective against diphtheria,
tetanus and all three polioviruses (Table 2). Pre- to post-
booster, anti-PRP GMTs increased from 1.07 to 59.6 mg/ml in
children receiving DTaP—IPV—PRPT vaccine, and from 1.85
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Table 1 Seroprotection and vaccine response rates post-primary, pre- and post-booster vaccination in the same study population (seven and 18—19 months of age)
Antibody Combined fully liquid DTaP—IPV—PRPT Separate injections DTaP—IPV + PRPT
Post-primary Pre-booster Post-booster Post-primary Pre-booster Post-booster
N = 89 N = 89 N = 87 N = 85 N = 85 N = 83
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
Anti-PRP 0.15 mg/ml 100 (95.9—100) 93.1 (85.6—97.4) 100 (95.8—100) 100 (95.8—100) 95.1 (88—98.7) 100 (95.7—100)
Anti-PRP 1.0 mg/ml 96.6 (90.5—99.3) 50.6 (39.6—61.5) 100 (95.8—100) 98.8 (93.6—100) 67.1 (55.8—77.1) 100 (95.7—100)
Anti-diphtheria 0.01 IU/ml 100 (95.9—100) 98.9 (93.9—100) 100 (95.8—100) 100 (95.8—100) 100 (95.7—100) 100 (95.7—100)
Anti-tetanus 0.01 IU/ml 100 (95.9—100) 100 (95.9—100) 100 (95.8—100) 100 (95.8—100) 100 (95.5—100) 100 (95.5—100)
Anti-polio 1 8 (1/dil.) 100 (95.9—100) 100 (95.9—100) 100 (95.8—100) 100 (95.8—100) 98.8 (93.5—100) 100 (95.6—100)
Anti-polio 2 8 (1/dil.) 100 (95.9—100) 100 (95.9—100) 100 (95.8—100) 100 (95.8—100) 100 (95.8—100) 100 (95.7—100)
Anti-polio 3 8 (1/dil.) 100 (95.9—100) 100 (95.8—100) 100 (95.8—100) 100 (95.8—100) 100 (95.7—100) 100 (95.6—100)
Anti-PT 4-fold increasea 100 (95.9—100) NA 100 (95.6—100) 100 (95.8—100) NA 97.5 (91.2—99.7)
Anti-FHA 4-fold increasea 94.4 (87.4—98.2) NA 95.4 (88.6—98.7) 92.9 (85.3—97.4) NA 97.5 (91.4—99.7)
Anti-PRN 4-fold increasea 97.8 (92.1—99.7) NA 95.2 (88.1—98.7) 97.6 (91.8—99.7) NA 97.5 (91.4—99.7)
Anti-FIM(2+3) 4-fold increasea 100 (95.9—100) NA 95.1 (87.8—98.6) 100 (95.8—100) NA 90.5 (81.5—96.1)
a Four-fold increase in antibody titers from pre- to post-primary series (for primary vaccination) and from pre- to post-booster dose (for booster vaccination). Note that the number of blood
samples analyzed for a particular antigen varied slightly depending on the amount of blood available for a particular test.
Table 2 Geometric mean titers (GMT) post-primary, pre- and post-booster vaccination in the same study population (seven and 18—19 months of age)
Antibody Combined fully liquid DTaP—IPV—PRPT Separate injections DTaP—IPV + PRPT
Post-primary Pre-booster Post-booster Post-primary Pre-booster Post-booster
N = 89 N = 89 N = 87 N = 85 N = 85 N = 83
GMT (95% CI) GMT (95% CI) GMT (95% CI) GMT (95% CI) GMT (95% CI) GMT (95% CI)
Anti-PRP mg/ml 11.5 (9.21—14.3) 1.07 (0.806—1.43) 59.6 (45.6—77.9) 20.4 (15.8—26.2) 1.85 (1.36—2.51) 62.2 (47.3—81.7)
Anti-diphtheria IU/ml 2.28 (1.87—2.77) 0.134 (0.105—0.170) 8.46 (6.61—10.8) 1.69 (1.40—2.04) 0.098 (0.078—0.121) 7.03 (5.29—9.35)
Anti-tetanus IU/ml 5.59 (5.05—6.19) 1.21 (1.07—1.37) 10.5 (9.29—11.8) 6.37 (5.52—7.36) 1.40 (1.23—1.60) 11.2 (10.1—12.5)
Anti-polio 1 (1/dil.) 1086 (881—1338) 123 (96.8—156) 4418 (3714—5255) 1220 (932—1598) 148 (110—198) 5696 (4634—7000)
Anti-polio 2 (1/dil.) 2617 (2171—3156) 276 (203—374) 7278 (5783—9161) 3117 (2594—3745) 273 (207—360) 9093 (7316—11 303)
Anti-polio 3 (1/dil.) 1653 (1382—1978) 142 (106—190) 5349 (4228—6767) 1890 (1518—2353) 192 (139—266) 6889 (5390—8804)
Anti-PT EU/ml 224 (202—249) 17.4 (15.5—19.5) 408 (366—456) 218 (191—247) 15.2 (13.2—17.6) 385 (332—447)
Anti-FHA EU/ml 119 (105—134) 13.5 (11.3—16.1) 235 (214—257) 107 (94.5—120) 11.8 (10.2—13.7) 224 (197—255)
Anti-PRN EU/ml 84.2 (73.3—96.8) 15.5 (13.3—18.1) 189 (162—221) 99.8 (86.2—116) 16.8 (14.5—19.4) 334 (280—398)
Anti-FIM(2+3) EU/ml 808 (705—924) 97.5 (82.6—115) 1903 (1660—2182) 791 (663—945) 103 (84.6—125) 2050 (1754—2395)
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Figure 1 Reverse cumulative distribution curves, pre- and post-booster in subjects receiving DTaP—IPV—PRPT (group A) or DTaP—
IPV + PRPT at separate sites (group B).
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Figure 1. (Continued ).to 62.2 mg/ml in children receiving DTaP—IPV and PRPT
vaccines separately. There were high vaccine response rates
in both groups to each of the pertussis antigens (PT, FHA,
PRN, FIM2+3), with at least 90.5% of subjects achieving a
four-fold increase in antibody titer. Post-booster anti-per-
tussis antibody responses were similar in the two study groups
except for anti-PRN, with higher GMTs observed in subjects
receiving separate injections of DTaP—IPVand PRPT, 334 vs.
189 EU/ml. Reverse cumulative distribution curves in
Figure 1 show no differences between the study groups in
post-booster antibody GMTs and GMTs except for PRN.
Safety
No immediate reactions were reported. The occurrence of
solicited local and systemic reactions, summarized in Table 3,was similar in both study groups. Within eight days (day 0—7)
following vaccination, 28.1% of the children given the fully
liquid vaccine had a solicited local reaction. In the group that
received separate injections, 28.2% had a reaction at the
DTaP—IPV injection site and 20% at the PRPT site. All
solicited local reactions occurred within three days after
vaccination. Most were of mild or moderate intensity. One
recipient of the DTaP—IPV— PRPT vaccine experienced
severe injection-site pain. Five severe local reactions were
reported in the group receiving separate injections, pain at
the DTaP—IPV site by one subject and the PRPT site by two
subjects; one occurrence of redness and one of swelling at
the PRPP site was experienced by two other children. About
half of the children experienced a systemic adverse event
within the week following vaccination, most of which were of
mild or moderate intensity. In both groups, the most fre-
quently reported systemic event was fever, but only three
instances of fever 40 8C were reported. Solicited local and
systemic reactions generally resolved within three days.
Severe solicited systemic symptoms were infrequent
(between 0 and 2.4%). The only serious adverse event
reported, herpangina, requiring hospitalization, was not
related to vaccination.
Discussion
This study was designed to evaluate the antibody persis-
tence, booster response, reactogenicity and safety of a fully
liquid pentavalent combination vaccine in comparison with
its constituent DTaP—IPV and PRPT vaccines given sepa-
rately. Both study groups had similar seroprotection or vac-
cine response rates and GMT values, consistent with absence
of clinically significant antigen interaction when these DTaP—
IPV and PRPT vaccines were combined in a single booster
injection.
As could be expected, GMTs decreased in each study group
between the primary series and booster administration;
however, approximately one year after receiving a three-
dose primary series of the same vaccine(s) at 2, 4 and 6
months of age, at least 93% of the children still had protective
levels of antibodies to diphtheria, tetanus, and the three
poliovirus types. These levels were similar in both study
groups. The high rate of antibody persistence of these anti-
gens is indicative of the protection of this study population
over the approximately one year interval between the pri-
mary and booster vaccinations. Indeed, 100% of infants
receiving the fully liquid combined vaccine (and all but
one subject receiving PRPT as a separate injection) had
anti-polio antibody titers 8 dil. U just before the booster
dose. Thus, the IPV vaccine antigens included in the com-
bined vaccines, produced on either Vero cells or MRC5 human
diploid cells promote high, durable immune responses. More-
over, 93.1% of children who had received the fully liquid
vaccine and 95.1% of those given separate injections of
DTaP—IPV and PRPT at two, four and six months of age,
remained seroprotected against Hib (anti-PRP 0.15 mg/ml)
one year later, prior to the booster dose. GMTs for anti-PRP
were of 1.07 and 1.85 mg/ml just before the booster dose;
the 95% CIs were overlapping.
One month after booster vaccination, both the combined
and separately administered vaccines elicited strong immune
responses. Anti-diphtheria antibody GMTs ranged from 7 to
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Table 3 Incidence of reactogenicity (any solicited adverse reaction) after booster injection
Reaction Combined N = 89 Separate injections N = 85
DTaP—IPV—PRPT DTaP—IPV PRPT
Solicited local reactions n % n % n %
At least one reaction 25 28.1 24 28.2 17 20
Redness 12 13.5 14 16.5 7 8.24
Swelling 8 8.99 7 8.24 7 8.24
Pain 21 23.6 20 23.5 17 20
At least one severe reactiona 1 1.12 1 1.18 2 2.35
Redness 0 0 0 0 1 1.18
Swelling 0 0 0 0 1 1.18
Pain 1 1.12 1 1.18 2 2.35
Solicited systemic reactions n % n %
At least one reaction 42 47.2 44 51.8
Feverb 21 23.6 27 31.8
Drowsiness 11 12.4 10 11.8
Fussiness 12 13.5 11 12.9
Unusual crying 15 16.9 13 15.3
Loss of appetite 15 16.9 21 24.7
Vomiting 7 7.9 4 4.7
Diarrhea 10 11.2 5 5.9
At least one severe reactiona 5 5.6 6 7.1
Fever 1 1.1 2 2.4
Drowsiness 0 0 1 1.2
Unusual crying 0 0 1 1.2
Loss of appetite 2 2.2 2 2.4
Vomiting 0 0 1 1.2
Diarrhea 2 2.2 1 1.2
a Severe fever = rectal temperature >40.0 8C; severe pain = infant cries when leg/arm is moved; severe redness/swelling = longest
diameter >50 mm; severe fussiness/irritability = continuously fussy for more than 3 hours; severe drowsiness = sleeping most of the time.
b Fever = rectal temperature 38.0 8C. N = number of subjects evaluated; n = number of subjects with a reaction.8.5 IU/ml and anti-tetanus GMTs from 10.5 to 11 IU/ml, many
times higher than the accepted protective levels. The boos-
ter responses to IPV as measured by GMTs (from 123 to
4418 1/dil. U, from 276 to 7278 1/dil. U, and from 142 to
5349 1/dil. U for anti-polio types 1, 2, and 3, respectively in
the case of the fully liquid vaccine) were also both very
strong, without notable differences between the vaccines
(Figure 1). Vaccine responses to PT, FHA, PRN and FIM2+3
were high in both study groups, with four-fold increases from
pre- to post-booster vaccination observed for each pertussis
antigen in at least 95.1% of the children given the combined
vaccine and 90.5% of subjects given the vaccines separately.
Although the post-booster increase in anti-pertactin GMTwas
greater in the subjects given separate injections of DTaP—IPV
and PRPT, 15.5 to 189 EU/ml vs. 16.8 to 334 EU/ml, both
responses can be considered to show a strong boosting effect,
and we conclude that the difference observed is not likely to
be clinically significant.
Notably, the fully liquid vaccine elicited a post-booster
anti-PRP antibody response indistinguishable from that seen
in subjects given DTaP—IPV and PRPTas concomitant, sepa-
rate injections, indicating appropriate priming and anamnes-
tic responses (Figure 1). One month after booster
vaccination, all children in both study groups achieved
anti-PRP antibody concentrations considered to be protec-
tive (1.0 mg/ml). These strong anamnestic responsesagainst each antigen indicate that a good immune memory
was induced by the primary-immunization at two, four and
six months of age.
Similar immune responses were obtained in an earlier
study of booster response at 18 months of age in Taiwanese
children using a DTaP//PRPT vaccine in which lyophilized
PRPT was reconstituted rather than being supplied as a
fully liquid vaccine, and which contained the same five aP
antigens.16 In that study, anti-PRP GMTs one month after
the primary series were 11.8 mg/ml in children given the
combined vaccine vs. 13.0 mg/ml in those given DTaP and
PRPT vaccines separately. After the booster dose, anti-
PRP titers increased to 58.5 mg/ml in the combined group
vs. 55.3 mg/ml in subjects given separate injections. Vac-
cine response rates (four-fold increase in antibody levels)
to the aP antigens, from 87% to 100% in that study, were
similar to the rates seen in the children who participated in
our study.
In the current study, the incidence rates of solicited
adverse events were low and similar to other acellular
pertussis-based vaccines.17—21 Pain was the most frequent
solicited local adverse event, reported by 20—24% of sub-
jects, but only 1—2% of these reactions were severe. The
DTaP-based combined vaccines (with or without PRPT)
showed similar solicited reaction rates. Both local and sys-
temic reactions usually resolved within three days.
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approximately a year after completion of primary immuniza-
tion, was high for all antigens. A booster with either the fully
liquid DTaP—IPV—PRPT vaccine or concomitant vaccination
of DTaP—IPV and PRPT at separate sites produced a strong
anamnestic response, such that all children had circulating
antibody levels far above the thresholds thought to be asso-
ciated with long-term protection against Hib, diphtheria,
tetanus and poliomyelitis. High antibody levels were also
induced against pertussis (PT, FHA, FIM2+3 and PRN). The
study vaccines were well tolerated. This fully liquid com-
bined vaccine provides an advantage to DTaP-based combi-
nation vaccines that rely on reconstitution of the PRPT
component with liquid DTaP. This added convenience
increases ease of use and facilitates proper administration.
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